4.3 Article

Parkinson's disease in Sweden-resource use and costs by severity

期刊

ACTA NEUROLOGICA SCANDINAVICA
卷 144, 期 5, 页码 592-599

出版社

WILEY
DOI: 10.1111/ane.13502

关键词

Hoehn and Yahr; Parkinson's disease; resource use; societal costs

资金

  1. AbbVie
  2. Medtronic
  3. Nordic Infucare (Air Liquide Healthcare)

向作者/读者索取更多资源

The study estimated resource use and costs in relation to severity levels in individuals with Parkinson's disease in a Swedish setting, showing that late stages of the disease were associated with significant societal costs. The findings suggest potential savings by optimizing symptomatic treatment for patients with advanced PD.
Objectives To estimate resource use and costs, including direct and indirect costs, in relation to levels of severity in individuals with Parkinson's disease (PD) in a Swedish setting. Materials and methods Patients with idiopathic PD registered in the National Parkinson's Disease Patient Registry (PARKreg), with registrations of Hoehn and Yahr (H&Y) and off time in the Skane Region, were included. Annual costs of healthcare contacts, drugs, formal and informal care, and productivity loss associated with PD were estimated using data from PARKreg linked with regional and national healthcare registers between 2013 and 2019. Results In total, 960 patients and 1324 observations (patient-years) were included. Total average cost per patient-year was SEK 168,982 (EUR 15,958) and ranged from SEK 62,404 (EUR 5893) for H&Y stage I to SEK 1,056,324 (EUR 99,755) in H&Y stage V. The dominating part of total costs for early stages were indirect costs accounting for 50-60% while formal care made up for 55% and 81% of total costs in H&Y IV and V, respectively. Total mean costs for formal care, informal care, and productivity loss also increased with increasing off-time. Conclusion Advanced and late stages of PD are associated with significant societal costs as patients in those stages often require resource-intensive and costly formal care. Thus, there are potential savings to be made, by optimizing the pharmacological and surgical symptomatic treatment of patients with advanced disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据